DRUG STUDY

Name of the Patient: X Age: years old Sex:Female Name of Student Angelica Mae E. Ronquillo
Civil Status: ______ Religion: _________________________ Rm/Bed No. _Area: LR/DR Level/ Block: BSN Level 4 Block A
Address : San Miguel, Bulacan___________________________ Date Submitted:May 14, 2023, Date of Admission: May 8, 2023
Diagnosis: Rating: __________________________________________________

Drug Name/Dosage/ Classification/ Indication/ Side Effects Adverse Nursing Considerations

Route/Frequency/ Mechanism of Contraindication Reactions
Drug Order Action
Generic name: PHARMACOTH Indication: Frequent:Dizziness, Slow breathing, Before:
Butorphanol ERAPEUTIC: Relief of moderate to Nausea, drowsiness, change in  Obtain and record
Narcotic opiate severe pain, vomiting consciousness, vital signs.
Brand name: agonist preoperative or shortness of breath,  Ask the client’s full
Stadol preanesthetic sedation swelling in hands
and analgesia Occasional: Cough and feet name to verify his
Therapeutic producing identity.
Usual dosage/ Effect: mucus,difficulty  Educate and
frequency: Analgesic that
IV 0.5–2 mg q3–4h breathing,shortness
relieves moderate explain the
of breath,tightness in
as needed to severe pain with Contraindication: medication to the
chest, wheezing
apparently low Narcotic-dependent client, how it
potential for patients.
Rare: sweating, works, why it is
Usual route: dependence.
IV; IM weakness given to him, and
the possible side
Action:
Drug order: Synthetic, centrally effects.
Butorphanol 1mg IV acting analgesic
q8 x 3 doses with mixed narcotic  Monitor for
agonist and respiratory
antagonist actions. depression. Do not
Acts as agonist on administer drug if
one type of opioid respiratory rate is
receptor and as a <12 breaths/min.
competitive
antagonist at During:
others. For IV push,
administer over 3–5
Pharmacodynami Give at a rate of 2
cs mg over 3–5 min.
Onset: 10–30 min After:
IM; 1 min IV.
Peak: 0.5–1 h IM;  Remind the client
4–5 min IV. to report all adverse
Duration: 3–4 h reactions and to
IM; 2–4 h IV. notify prescriber.
 Monitor any signs
Pharmacokinetics of hypersensitivity.
Distribution: Cros  Document the time,
ses placenta; location, dose, and
distributed into medication given to
breast milk. the patient.
Metabolism: Meta
bolized in liver in Patient & Family
inactive Education
metabolites.
Elimination: Excre  Lie down to control
ted primarily in drug-induced
urine. nausea.
Half-Life: 3–4 h.  Do not take alcohol
or other CNS
Drug depressants with
Interactions:
this drug without
Alcohol and
consulting
other CNS physician because
DEPRESSANTS a of possible additive
ugment CNS and effects.
respiratory
depression.